Search

RS Oncology, LLC, announces UK MHRA’s clinical trial acceptance of RSO-21


RS Oncology, LLC, announces UK Medicines and Healthcare Regulatory Agency’s clinical trial acceptance of new drug, RSO-021, for treatment of Pleural Effusion and Mesothelioma


Cambridge, MA, October 1, 2021 ---- RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with pleural effusion and mesothelioma, has announced acceptance of their novel drug, RSO-021, for use in a Phase 1/2 clinical trial by the Medicines and Healthcare Regulatory Agency in the UK.


RSO-021 therapy has proven to significantly reduce pre-clinically tumor burden in malignant mesothelioma and other cancer types by inhibiting three key enzymes in the antioxidant signaling network within the mitochondria. Covalent adduction of the active site of a key mitochondrial enzyme by RSO-021 inactivates the peroxidase activity of the enzymes leading to accumulation of hydrogen peroxide to levels incompatible with tumor cell survival, while preserving healthy normal cells. RSO-021 is being developed for the treatment of malignant pleural effusion (MPE) via intrapleural (IP) installation in patients suffering from mesothelioma, breast cancer and other indications causing MPE.


“We’re excited about RSO-021 as a novel metabolic therapy. This clinical trial is an important step in improving treatment for people living with this aggressive cancer,” said RS Oncology CEO and General Counsel, Jarrett Duncan. “RSO-021, the result of a collaboration between RSO, the University of Vermont Cancer Center and Wake Forest University School of Medicine, shows tremendous promise. The treatment has shown pre-clinical efficacy in nearly a dozen different indications, signifying broad applicability and therapeutic potential for cancer therapy.” “Most notably, treatments using this unique mechanism of action can be guided by a companion diagnostic, identifying patients with sufficiently dysregulated metabolic pathways prone to respond to this novel therapeutic approach.” added COO and Head of business development, George Naumov, Ph.D.



RS Oncology, LLC is a preclinical stage biotechnology company based in Cambridge, Massachusetts and London, UK with a mission to eradicate mesothelioma worldwide through new science and an innovative business model. The lead program is currently focused on development of novel therapies that modulate mitochondrial pathways that drive diseases of oxidative stress for treatment of malignant pleural effusion and malignant mesothelioma.

219 views0 comments